Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2008;112:64-70
© 2008 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Bansal, N.
Right arrow Articles by Wright, J. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bansal, N.
Right arrow Articles by Wright, J. D.
Related Collections
Right arrow Gynecologic oncology

ORIGINAL RESEARCH

Uterine Carcinosarcomas and Grade 3 Endometrioid Cancers

Evidence for Distinct Tumor Behavior

Nisha Bansal, MD1,4, Thomas J. Herzog, MD1,4, Venkatraman E. Seshan2,4, Peter B. Schiff, MD, PhD3,4, William M. Burke, MD1,4, Carmel J. Cohen, MD1,4 and Jason D. Wright, MD1,4

From the 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 2Department of Biostatistics, and 3Department of Radiation Oncology, Columbia University College of Physicians and Surgeons; and 4the Herbert Irving Comprehensive Cancer Center, New York, New York.

OBJECTIVE: To compare the clinical behavior and outcome of uterine carcinosarcomas and grade 3 endometrioid carcinomas.

METHODS: Data on patients with grade 3 endometrioid adenocarcinomas and uterine carcinosarcomas, from 1988 to 2004, was obtained from the Surveillance, Epidemiology, and End Results database. Mortality was analyzed using Cox proportional hazards models. Survival analysis was performed with the Kaplan-Meier method and log rank test.

RESULTS: The cohort included 8,986 women with 5,024 (56%) grade 3 endometrioid carcinomas and 3,962 (44%) uterine carcinosarcomas. Women with uterine carcinosarcomas were older (aged 70 years compared with 66 years; P<.001) and more often nonwhite (23% compared with 15%; P<.001). These women presented with more advanced disease (stage III/IV 41% compared with 31%; P<.001). Multivariable analysis demonstrated that uterine carcinosarcoma histology, advanced age, nonwhite race, and advanced stage were independent predictors of poor survival. Cancer-specific mortality was 45% lower in women with grade 3 endometrioid carcinomas (hazard ratio 0.55; 95% confidence interval [CI] 0.5–0.6). The 5-year cancer-specific survival was lower for women with uterine carcinosarcoma for each disease stage. Survival for stage IC was 38% (95% CI 33–45%) for uterine carcinosarcoma compared with 68% (95% CI 63–73%) for grade 3 endometrioid carcinoma. For stage III, survival was 22% (95% CI 19–26%) for uterine carcinosarcoma compared with 45% (95% CI 41–49%) for grade 3 endometrioid carcinoma.

CONCLUSION: Carcinosarcomas present at more advanced stage and have worse survival than grade 3 endometrioid carcinomas. Carcinosarcomas may represent a distinct biologic entity.

LEVEL OF EVIDENCE: II






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American College of Obstetricians and Gynecologists.